vimarsana.com

Latest Breaking News On - Psma pet - Page 1 : vimarsana.com

Dr Koo on PSMA PET Imaging in Prostate Cancer

Phillip J. Koo, MD, discusses the use of PSMA PET imaging in prostate cancer.

UCSF and UCLA to Host Inaugural PSMA PET Conference in January 2024

Viability of focal dose escalation to prostate cancer intraprostatic l by Joel Poder, Samantha Radvan et al

PURPOSE: This study aimed to determine the viability of focal dose escalation to prostate cancer intraprostatic lesions (IPLs) from multiparametric magnetic resonance (mpMRI) and prostate-specific membrane antigen positron emission tomography (PSMA-PET) images using high-dose-rate (HDR) prostate brachytherapy (pBT). METHODS AND MATERIALS: Retrospective data from 20 patients treated with HDR pBT was utilized. The interobserver contouring variability of 5 observers was quantified using the dice similarity coefficient (DSC) and mean distance to agreement (MDA). Uncertainty in propagating IPL contours to trans-rectal ultrasound (TRUS) was quantified using a tissue equivalent prostate phantom. Feasibility of incorporating IPLs into HDR pBT planning was tested on retrospective patient data. RESULTS: The average observer DSC was 0.65 (PSMA-PET) and 0.52 (mpMRI). The uncertainty in propagating IPL contours was 0.6 mm (PSMA-PET), and 0.4 mm (mpMRI). Uncertainties could be accounted for by expan

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.